medigraphic.com
SPANISH

Revista de Hematología

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2022, Number 4

<< Back Next >>

Rev Hematol Mex 2022; 23 (4)

Elective laparoscopic splenectomy, experience in a tertiary care hospital

Aguirre-Flores K, Mazariegos-Gutiérrez UE, Gómez-Arenas SR, Nacud-Bezies YA
Full text How to cite this article

Language: Spanish
References: 13
Page: 246-253
PDF size: 454.59 Kb.


Key words:

Laparoscopic splenectomy, Immune thrombocytopenic purpura, Myelodysplastic syndrome, Hematologic diseases.

ABSTRACT

Objective: To report our experience in patients surgically treated with laparoscopic splenectomy in a tertiary care hospital.
Materials and Methods: Retrospective and observational study of patients surgically treated with laparoscopic splenectomy from March 2018 to May 2022, analyzing demographic, diagnostic, preoperative, transoperative and postoperative variables.
Results: Twenty-seven patients were studied, 23 of whom were women; the average age was 36.4 years. The main diagnosis was immune thrombocytopenic purpura in 20/27 patients. The average operative time was 126.9 minutes. The average length of hospital stay after surgery was 25.3 hours. Only one patient presented surgical site infection. Twenty-three patients had complete response to treatment and 4 presented a partial response with a diagnosis of immune thrombocytopenic purpura associated with myelodysplastic syndrome, currently in bone marrow transplant protocol.
Conclusions: Laparoscopic splenectomy is the ideal surgical procedure in patients with hematological disease refractory to second- and third-line medical treatment.


REFERENCES

  1. Misiakos EP, Bagias G, Liakakos T, Machairas A. Laparoscopicsplenectomy: Current concepts. World J GastrointestEndosc 2017; 9 (9): 428-437. doi: 10.4253/wjge.v9.i9.428.

  2. Palandri F, Polverelli N, Sollazzo D, Romano M, CataniL, Cavo M, Vianelli N. Have splenectomy rate and mainoutcomes of ITP changed after the introduction of newtreatments? A monocentric study in the outpatient settingduring 35 years. Am J Hematol 2016; 91: E267-E272.doi: 10.1002/ajh.24310.

  3. Yong M, Schoonen WM, Li L, Kanas G, Coalson J, MowatF, Fryzek J, Kaye JA. Epidemiology of paediatric immunethrombocytopenia in the General Practice ResearchDatabase. Br J Haematol 2010; 149: 855-864. doi:10.1111/j.1365-2141.2010.08176.x.

  4. Habermalz B, Sauerland S, Decker G, Delaitre B, Gigot JF,Leandros E, Lechner K, Rhodes M, Silecchia G, Szold A, etal. Laparoscopic splenectomy: the clinical practice guide-lines of the European Association for Endoscopic Surgery(EAES). Surg Endosc 2008; 22: 821-848. doi: 10.1007/s00464-007-9735-5.

  5. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomyfor adult patients with idiopathic thrombocytopenicpurpura: a systematic review to assess long-term plateletcount responses, prediction of response, and surgicalcomplications. Blood 2004; 104: 2623-2634. doi: 10.1182/blood-2004-03-1168.

  6. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B,Mazzucconi MG, Barbui T, Tura S, Baccaranion M; GruppoItaliano per lo Studio delle Malattie Ematologichedell'Adulto. Efficacy and safety of splenectomy in immunethrombocytopenic purpura: long-term results of 402 cases.Haematologica 2005; 90: 72-77.

  7. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, KingMJ; Grupo de Trabajo de Hematología General del ComitéBritánico de Estándares en Hematología. Guidelines forthe diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol 2012; 156: 37-49.doi: 10.1111/j.1365-2141.2011.08921.x.

  8. Guizzetti L. Total versus partial splenectomy in pediatrichereditary spherocytosis: A systematic review and metaanalysis.Pediatr Blood Cancer 2016; 63 (10): 1713-22. doi:10.1002/pbc.26106.

  9. Dubois L, Gray DK. Case series: splenectomy: does it stillplay a role in the management of thrombotic thrombocytopenicpurpura? Can J Surg 2010; 53: 349-355.

  10. Lechner K, Jäger U. How I treat autoimmune hemolytic anemiasin adults. Blood 2010; 116: 1831-1838. doi: 10.1182/blood-2010-03-259325.

  11. Stanek A, Stefaniak T, Makarewicz W, Kaska L, PodgórczykH, Hellman A, Lachinski A. Accessory spleens: preoperativediagnostics limitations and operational strategy in laparoscopicapproach to splenectomy in idiopathic thrombocytopenicpurpura patients. Langenbecks Arch Surg 2005; 390:47-51. doi: 10.1007/s00423-003-0449-4.

  12. Weledji EP, Orock GE. Surgery for non-Hodgkin's lymphoma.Oncol Rev 2015; 9: 274. doi: 10.4081/oncol.2015.274.

  13. Weledji EP. Benefits and risks of splenectomy. Int J Surg2014; 12: 113-119. doi: 10.1016/j.ijsu.2013.11.017.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Hematol Mex. 2022;23